We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: neoadjuvant immunotherapy
MedXY News
EnglishTag

neoadjuvant immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker
newsesophageal squamous cell carcinomaIL-6

Neoadjuvant Pembrolizumab Plus Chemoradiotherapy Yields 43.2% pCR in Resectable ESCC — IL-6 Emerges as a Predictive Biomarker

By MedXY|Dec 9, 2025

The multicenter PALACE-2 trial reports a 43.2% pathological complete response (pCR) with preoperative pembrolizumab combined with chemoradiotherapy for resectable esophageal squamous cell carcinoma and identifies baseline serum IL-6 as a po

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
newsesophageal squamous cell carcinomaneoadjuvant immunotherapy

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

By MedXY|Dec 1, 2025

PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a hig

Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer
newshead and neck cancerneoadjuvant immunotherapy

Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer

By MedXY|Nov 21, 2025

A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a use

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial
Dermatologycutaneous squamous-cell carcinomaIpilimumab

Neoadjuvant Nivolumab With or Without Low‑Dose Ipilimumab Produces High Pathologic Response and Organ Preservation in Resectable Cutaneous Squamous Cell Carcinoma: Results from the MATISSE Phase 2 Trial

By MedXY|Nov 12, 2025

The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma
newsmelanomaneoadjuvant immunotherapy

Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma

By MedXY|Jan 5, 2026

The randomized phase 1b/2 Morpheus‑Melanoma trial found that tobemstomig (anti‑PD‑1/anti‑LAG‑3 bispecific) produced comparable pathological response rates to nivolumab plus ipilimumab with a substantially improved safety profile in resectab

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities